Cytokinetics, Inc.
Cytokinetics Announces Fourth Quarter 2024 Financial Results and Provides Business Update
Summary
Cytokinetics, Incorporated announced its financial results for the fourth quarter and year ended December 31, 2024. The company reported total revenues of $16.9 million for Q4 2024, up from $1.7 million in Q4 2023, primarily due to a $15.0 million upfront payment from Corxel in connection with the assignment to Sanofi of Corxel's rights to develop and commercialize aficamten in Greater China. The net loss for Q4 2024 was $150.0 million, or $(1.26) per share, compared to a net loss of $136.9 million, or $(1.38) per share, in Q4 2023. For the full year 2024, total revenues were $18.5 million, and the net loss was $589.5 million, or $(5.26) per share. The company also provided financial guidance for 2025, expecting GAAP operating expenses between $670 million and $710 million, with an anticipated increase due to investments toward commercial readiness for aficamten. Cytokinetics is preparing for the potential U.S. approval and commercial launch of aficamten in the second half of 2025, subject to FDA approval.
Profitelligence Alerts
Get alerts for CYTK
Be first to know when Cytokinetics, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Cytokinetics, Inc.
Cytokinetics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel muscle activators as potential treatments for debilitating diseases. Primarily, the company's work aims to address unmet medical needs in the fields of neurology and cardiology, offering therapeutic solutions that target muscle function. Cytokinetics' research centers on small molecule drugs that modulate muscle performance, which could significantly aid patients suffering from heart failure, amyotrophic lateral sclerosis (ALS), and other muscle-related conditions. The company is actively involved in clinical trials and collaborates with other notable entities in its quest for innovative medical advancements. Its contributions to the healthcare sector exemplify the growing role of targeted therapy in improving patient outcomes. Headquartered in South San Francisco, California, Cytokinetics operates as a key player in the biotechnology landscape, with a commitment to pioneering treatments that leverage the complex mechanisms of muscle biology.
Official SEC Documents
Advertisement